Literature DB >> 21571545

Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort.

Hong Tao Hu1, Jin Hyoung Kim, Lim-Sick Lee, Kyung-Ah Kim, Gi-Young Ko, Hyun-Ki Yoon, Kyu-Bo Sung, Dong Il Gwon, Ji Hoon Shin, Ho-Young Song.   

Abstract

PURPOSE: To evaluate the factors associated with tumor response and survival after chemoembolization in 362 patients with hepatocellular carcinoma (HCC).
MATERIALS AND METHODS: Between January 2006 and August 2006, 362 patients who underwent chemoembolization for unresectable HCC were evaluated. The endpoints were tumor response and patient survival. Factors associated with tumor response were evaluated using multivariate logistic regression analysis. Factors associated with patient survival were evaluated using multivariate Cox regression analysis.
RESULTS: After chemoembolization, 69% of the study patients showed a tumor response. On multivariate analysis, tumor size (centimeter) (odds ratio [OR] 2.85, P = .002), tumor number (OR 4.58, P < .001), tumor vascularity (OR 11.97, P < .001), and portal vein invasion (OR 4.24, P < .001) were significant factors for tumor response. The median survival was 23 months. On multivariate analysis, Child-Pugh class (hazard ratio [HR] 2.43, P < .001), maximal tumor size (HR 1.66, P = .002), tumor vascularity (HR 2.13, P = .001), portal vein invasion (HR 2.39, P < .001), tumor number (HR, 1.92, P < .001), and alpha fetoprotein (AFP) value (HR 1.54, P = .003) were significant factors associated with patient survival after chemoembolization.
CONCLUSIONS: Tumor size, tumor vascularity, tumor number, and portal vein invasion are significant independent predictors of tumor response after chemoembolization in patients with unresectable HCC. Child-Pugh class B or C, large tumor size (≥ 4 cm), multiple tumors (five or more), portal vein invasion, and a high AFP value (> 83 ng/mL) indicated poor prognosis for overall patient survival after chemoembolization.
Copyright © 2011 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21571545     DOI: 10.1016/j.jvir.2011.03.005

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  36 in total

1.  Modified transarterial chemoembolization with locoregional administration of sorafenib for treating hepatocellular carcinoma: feasibility, efficacy, and safety in the VX-2 rabbit liver tumor model.

Authors:  Max Seidensticker; Sebastian Streit; Norbert Nass; Christian Wybranski; Julian Jürgens; Jan Brauner; Nadine Schulz; Thomas Kalinski; Ricarda Seidensticker; Benjamin Garlipp; Ingo Steffen; Jens Ricke; Oliver Dudeck
Journal:  Diagn Interv Radiol       Date:  2016 Jul-Aug       Impact factor: 2.630

2.  [Transarterial ablative therapy of hepatocellular carcinoma].

Authors:  A H Mahnken
Journal:  Radiologe       Date:  2014-07       Impact factor: 0.635

3.  Hepatic arterial infusion chemotherapy with fine-powder cisplatin and iodized-oil suspension in patients with intermediate-stage and advanced-stage (Barcelona Clinic Liver Cancer stage-B or stage-C) hepatocellular carcinoma: multicenter phase-II clinical study.

Authors:  Haruyuki Takaki; Koichiro Yamakado; Masakatsu Tsurusaki; Taku Yasumoto; Yasutaka Baba; Yoshiaki Narimatsu; Masashi Shimohira; Masato Yamaguchi; Kunihiro Matsuo; Yoshitaka Inaba; Koji Mikami; Ryohei Watanabe; Norifumi Nishida; Hiroshi Anai; Hideaki Kakizawa; Shozo Hirota
Journal:  Int J Clin Oncol       Date:  2014-11-29       Impact factor: 3.402

4.  Response assessment methods for patients with hepatic metastasis from rare tumor primaries undergoing transarterial chemoembolization.

Authors:  Lucas C Adam; Lynn J Savic; Julius Chapiro; Brian Letzen; MingDe Lin; Christos Georgiades; Kelvin K Hong; Nariman Nezami
Journal:  Clin Imaging       Date:  2022-06-26       Impact factor: 2.420

5.  Efficacy of TACE in TIPS patients: comparison of treatment response to chemoembolization for hepatocellular carcinoma in patients with and without a transjugular intrahepatic portosystemic shunt.

Authors:  Yuo-Chen Kuo; Maureen P Kohi; David M Naeger; Ricky T Tong; K Pallav Kolli; Andrew G Taylor; Jeanne M Laberge; Robert K Kerlan; Nicholas Fidelman
Journal:  Cardiovasc Intervent Radiol       Date:  2013-07-18       Impact factor: 2.740

6.  Evaluation of the potential utility of flat panel CT for quantifying relative contrast enhancement.

Authors:  A Kyle Jones; Armeen Mahvash
Journal:  Med Phys       Date:  2012-07       Impact factor: 4.071

7.  Does Enhancement or Perfusion on Preprocedure CT Predict Outcomes After Embolization of Hepatocellular Carcinoma?

Authors:  Alessandra Borgheresi; Adrian Gonzalez-Aguirre; Karen T Brown; George I Getrajdman; Joseph P Erinjeri; Anne Covey; Hooman Yarmohammadi; Etay Ziv; Constantinos T Sofocleous; Franz Edward Boas
Journal:  Acad Radiol       Date:  2018-03-27       Impact factor: 3.173

8.  Predictive factors for complete response of chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular carcinoma.

Authors:  Guillaume Vesselle; Camille Quirier-Leleu; Stéphane Velasco; Florian Charier; Christine Silvain; Samy Boucebci; Pierre Ingrand; Jean-Pierre Tasu
Journal:  Eur Radiol       Date:  2015-10-11       Impact factor: 5.315

Review 9.  Radioembolization for the Treatment of Primary and Metastatic Liver Cancers.

Authors:  Eun Jeong Lee; Hyun Woo Chung; Joon-Hyung Jo; Young So
Journal:  Nucl Med Mol Imaging       Date:  2019-11-08

Review 10.  Combination of ablation and embolization for intermediate-sized liver metastases from colorectal cancer: what can we learn from treating primary liver cancer?

Authors:  Matthew J Seager; Tobias F Jakobs; Ricky A Sharma; Steve Bandula
Journal:  Diagn Interv Radiol       Date:  2021-09       Impact factor: 2.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.